FDA Attempting To Overcome Major Roadblocks in Monitoring Drug Safety

FDA Attempting To Overcome Major Roadblocks in Monitoring Drug Safety

said Paul Seligman, M.D., M.P.H., director of the Offi ce of Pharmacoepidemiology and Statistical Science at the FDA. Health care providers, consumers,

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JNCI : Journal of the National Cancer Institute 2005-06, Vol.97 (12), p.872-873
1. Verfasser: Zielinski, Sarah L
Format: Artikel
Sprache:eng
Schlagworte:
Adverse Drug Reaction Reporting Systems - legislation & jurisprudence
Adverse Drug Reaction Reporting Systems - standards
Clinical Trials Data Monitoring Committees
Drug Approval - legislation & jurisprudence
Drug Industry - legislation & jurisprudence
Drug-Related Side Effects and Adverse Reactions
Humans
Legislation, Drug - trends
Oncology
Pharmacology
Product Surveillance, Postmarketing - methods
Product Surveillance, Postmarketing - standards
Safety standards
Toxicity
United States
United States Food and Drug Administration
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:said Paul Seligman, M.D., M.P.H., director of the Offi ce of Pharmacoepidemiology and Statistical Science at the FDA. Health care providers, consumers,
ISSN:0027-8874
1460-2105
DOI:10.1093/jnci/97.12.872